Cautious Hold Rating on Colgate-Palmolive Amid Strong 2024 Performance and Future Growth Challenges
RBC Capital Sticks to Its Hold Rating for Colgate-Palmolive (CL)
Colgate-Palmolive Analyst Ratings
Barclays Maintains Equal-Weight on Colgate-Palmolive, Lowers Price Target to $83
Evercore ISI Adjusts Price Target on Colgate-Palmolive to $105 From $112
Stifel Adjusts Price Target on Colgate-Palmolive to $95 From $101, Maintains Hold Rating
Barclays Adjusts Price Target on Colgate-Palmolive to $83 From $96
UBS Adjusts Price Target on Colgate-Palmolive to $104 From $112, Keeps Buy Rating
Colgate-Palmolive Is Maintained at Overweight by JP Morgan
Colgate-Palmolive Analyst Ratings
J.P. Morgan Maintains Colgate-Palmolive(CL.US) With Buy Rating, Cuts Target Price to $103
Deutsche Bank Maintains Colgate-Palmolive(CL.US) With Hold Rating, Cuts Target Price to $95
Piper Sandler Maintains Colgate-Palmolive(CL.US) With Buy Rating
Piper Sandler has lowered the Target Price for Colgate-Palmolive to $112.
TD Cowen Maintains Colgate-Palmolive(CL.US) With Buy Rating, Cuts Target Price to $100
Wells Fargo Maintains Colgate-Palmolive(CL.US) With Sell Rating, Cuts Target Price to $83
Wells Fargo Reaffirms Their Sell Rating on Colgate-Palmolive (CL)
Colgate-Palmolive Is Maintained at Overweight by Piper Sandler
Colgate-Palmolive Analyst Ratings
Piper Sandler Maintains Colgate-Palmolive(CL.US) With Buy Rating, Cuts Target Price to $112
No Data